Seres Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $736,000, primarily from grant revenue, compared to no revenue in the same period last year. The company incurred a net income of $4.6 million for the quarter, a significant turnaround from a net loss of $19.9 million in the prior year. This improvement was largely attributed to a $25 million gain from the sale of its VOWST business, which was finalized in September 2024, and a reduction in operating expenses.

Operating expenses for the second quarter decreased to $22 million from $24.9 million year-over-year. This decline was driven by lower research and development costs, which fell to $9.1 million from $12.9 million, and general and administrative expenses, which decreased to $7.1 million from $10.3 million. The company also recognized a $5.8 million impairment of long-lived assets during the quarter, reflecting adjustments related to its lease agreements.

In terms of strategic developments, Seres Therapeutics has paused further investment in the Phase 2 study of its lead product candidate, SER-155, while it seeks additional funding. The company is also exploring collaborations for its early-stage programs, including SER-603 for inflammatory bowel disease and SER-428, a liquid formulation for ICU patients. The company’s workforce was reduced by approximately 30% in early 2026 as part of cost-cutting measures.

As of June 30, 2026, Seres Therapeutics had cash and cash equivalents of $15.6 million, down from $45.8 million at the end of 2025. The company has an accumulated deficit of $987.7 million and anticipates needing additional funding to support ongoing operations and product development. Management has expressed substantial doubt about the company's ability to continue as a going concern without securing further financing, particularly as it expects to incur losses for the foreseeable future. The company plans to focus on advancing its product pipeline while managing its cash resources carefully.

About Seres Therapeutics, Inc.

Seres Therapeutics is a biopharmaceutical company specializing in live biotherapeutics to treat serious medical conditions. Its core focus is developing oral microbial therapies to prevent infections, improve immune regulation, and address inflammatory diseases. The company’s pipeline includes investigational products targeting bacterial bloodstream infections, gastrointestinal pathogens, and inflammatory bowel disease, leveraging proprietary microbiome platforms for drug discovery, manufacturing, and regulatory success.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov